Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.28 USD
Change Today 0.00 / 0.00%
Volume 0.0
HALO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Open
$13.88
Previous Close
$14.00
Day High
$14.60
Day Low
$13.88
52 Week High
03/17/15 - $16.55
52 Week Low
04/28/14 - $6.88
Market Cap
1.8B
Average Volume 10 Days
2.0M
EPS TTM
$-0.55
Shares Outstanding
126.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALO)

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer; and Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxter Healthcare Corporation, Pfizer Inc., and Janssen Biotech, Inc. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

153 Employees
Last Reported Date: 03/2/15
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Financial Officer and Vice President
Total Annual Compensation: $314.9K
Chief Scientific Officer and Vice President
Total Annual Compensation: $321.4K
Consultant
Total Annual Compensation: $366.7K
Compensation as of Fiscal Year 2013.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Announces the Appointment of James S. Mazzola as Vice President, Corporate Communications and Investor Relations

Halozyme Therapeutics, Inc. announced the appointment of James S. Mazzola as vice president, Corporate Communications and Investor Relations, reporting to President and CEO Dr. Helen Torley. Mr. Mazzola will be responsible for the creation and implementation of integrated communication and branding efforts that support Halozyme's business objectives to all key stakeholders, including investors, employees, media, corporate partners, patients, clinicians and the scientific community. Mr. Mazzola brings nearly 25 years of public relations, financial communication and marketing communication experience to Halozyme. He was previously senior vice president of Global Marketing, Communication and Investor Relations for CareFusion, responsible for the company's integrated marketing, communication and brand strategy, investor relations, sales operations and serving as president of the CareFusion Foundation. Prior to joining CareFusion, he was senior vice president of Global Communication at Cardinal Health where he led corporate public relations, financial communication and the Cardinal Health Foundation.

Genmab to Initiate Phase I MM Study Using Halozyme's Drug Delivery Platform

Halozyme Therapeutics, Inc. has announced that Genmab A/S has announced plans for a Phase I clinical trial of a subcutaneous formulation of the anti-CD38 antibody, daratumumab, indicated for the treatment of multiple myeloma, or MM, using the ENHANZE technology. In December 2014, Janssen Biotech, Inc. (Janssen) entered into an agreement with Halozyme Therapeutics for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology. This agreement has the potential to lead to the development of a subcutaneous formulation of daratumumab. Daratumumab, a human monoclonal antibody that targets CD38 on the surface of multiple myeloma cells, is in clinical development as a single agent and in combination with standard of care therapies in several settings of multiple myeloma.

Halozyme Therapeutics, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Halozyme Therapeutics, Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $30,377,000 compared to $12,498,000 for the same period a year ago. Operating loss was $3,851,000 compared to $21,324,000 last year. Net loss was $5,274,000 or $0.04 per basic and diluted share compared to $21,987,000 or $0.19 per basic and diluted share last year. For the year, the company reported total revenues of $75,334,000 compared to $54,799,000 for the same period a year ago. Operating loss was $63,036,000 compared to $80,434,000 last year. Net loss was $68,375,000 or $0.56 per basic and diluted share compared to $83,479,000 or $0.74 per basic and diluted share last year. Net cash used for the year was approximately $44 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $14.28 USD 0.00

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $14.96 USD 0.00
Valeant Pharmaceuticals International Inc C$250.21 CAD 0.00
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.1x
Price/Book 42.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.